|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The necessity for personalized therapeutic regimes, especially for older patients suffering from AML with mutated TET2 and/or other genetic alterations, along with its prognostication are also underlined.
|
31646775 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patients with double mutation or isolated SF3B1 mutation were less likely to be diagnosed with acute myeloid leukemia than patients with isolated TET2 mutation.
|
30587503 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We find that deletion of <i>Tet2</i> in native hematopoiesis as well as fully transformed acute myeloid leukemia (AML) results in changes in transcription factor (TF) activity within these regions, and we provide evidence that loss of TET2 leads to attenuation of chromatin binding of members of the basic helix-loop-helix (bHLH) TF family.
|
30796038 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
Biomarker
|
disease |
BEFREE |
Metformin, a widely used antidiabetic drug, has previously been demonstrated to exert anti-cancer effects in certain hematological malignancies, but its effects on the transformation of myelodysplastic syndromes to acute myeloid leukemia (AML-MDS) remain unclear.
|
31744691 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ASXL1 and TET2 showed similar mutation frequencies across all analyzed entities while RUNX1, CBL, and JAK2 were specifically mutated in patients with acute myeloid leukemia (AML), chronic myelomonocytic leukemia, and myeloproliferative neoplasms, respectively.
|
30994218 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic TET2 mutations have been repeatedly identified in age-related clonal hematopoiesis and in myeloid neoplasms ranging from acute myeloid leukemia (AML) to myeloproliferative neoplasms.
|
31187595 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In patients with acute myeloid leukemia (AML), 10% to 30% with the normal karyotype express mutations in regulators of DNA methylation, such as TET2 or DNMT3A, in conjunction with activating mutation in the receptor tyrosine kinase FLT3.
|
31682240 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This drug is approved for AML patients with MDS-related changes and therapy-related AML, both of which are frequently associated with complex karyotype.
|
30741367 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For patients with intermediate-risk cytogenetics (IR-AML), mutant TET2 had a significant association with adverse OS (HR = 0.474; P < 0.001).
|
31023266 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis revealed point mutations and indels of RUNX1 and further mutations typical for AML such as TET2, DNMT3A, and SRSF2, and 2 cases had tetrasomy 13 characteristic of RUNX1 mutant AML.
|
30396184 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patient was initially diagnosed with low-risk myelodysplastic syndrome-refractory cytopenias and multilineage dysplasia (MDS-RCMD), progressed to AML after failing hypomethylating agent therapy.
|
28187034 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
Biomarker
|
disease |
BEFREE |
MP-CMML patients had significantly shorter overall survival (OS; <i>P</i> < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (<i>P</i> < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients.
|
30054307 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
TET2 mRNA level was significantly down-regulated in AML patients compared with controls (p = 0.010).
|
29219176 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The combination of NPM1 and TET2 or IDH1/2 mutations along with an APL-like immunophenotype identifies a distinct subtype of AML.
|
29274134 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, we demonstrated that Tet2 <sup>-/-</sup> ;Flt3<sup>ITD</sup> acute myeloid leukemia (AML) precursors primarily underwent symmetric renewal divisions in culture.
|
29361987 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
Biomarker
|
disease |
BEFREE |
We discovered that mutations in IDH1, IDH2, TP53, DNMT3A, TET2 and spliceosome genes significantly increased the odds of developing AML.
|
29988143 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations involving TET2 were exclusively identified in AML-DN patients.
|
29767839 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
Biomarker
|
disease |
BEFREE |
The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.
|
29331774 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
No difference in TET2 expression levels in AML with TET2 SNP rs2454206<sup>AA</sup> and TET2 SNP rs2454206<sup>AG/GG</sup> was detected, indicating that TET2 SNP rs2454206 status does not affect TET2 expression in pediatric AML.
|
29664232 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
Biomarker
|
disease |
BEFREE |
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
|
28167452 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
We examined the association between TET2 and MEG3 promoter hypermethylation in Hainan patients with AML.
|
28407691 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
AML with high levels of BCAT1 (BCAT1<sup>high</sup>) displayed a DNA hypermethylation phenotype similar to cases carrying a mutant isocitrate dehydrogenase (IDH<sup>mut</sup>), in which TET2 is inhibited by the oncometabolite 2-hydroxyglutarate.
|
29144447 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Our study aims to unveil the relevance of DNMT3A and TET2 genes in global and specific methylation patterns in acute myeloid leukemia.
|
28992762 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ten-eleven translocation-2 (TET2) mutations frequently occur in AML and significantly promote leukemogenesis of this disorder.
|
28400619 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
TET2 or IDH1/2 mutations are commonly observed in acute myeloid leukemia (AML).
|
28039446 |
2017 |